BioStock: Good safety profile for Dicot’s LIB-01

For Uppsala-based Dicot, the phase I study with the potency drug candidate LIB-01 is currently underway to investigate the safety profile in humans. The company recently completed the first part of the study and reports that it has not seen any serious side effects, and that the safety profile appears to be very good. BioStock reached out to CEO Elin Trampe to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/01/good-safety-profile-for-dicots-lib-01/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se